Majority of Takeda investors want execs to return pay if deals flop

TOKYO -- A provision to let Takeda Pharmaceutical claw back executive pay after a major loss or false accounting drew majority support from shareholders even while failing to pass, in a sign of the scrutiny Japan's top drugmaker faces over its roughly $60 billion purchase of Irish peer Shire.